MarketMoodz
Protara's TARA‑002 Shows 55% 12‑Month CR in Bladder Cancer
Protara Therapeutics reported updated 12‑month Phase 2 results for TARA‑002 in BCG‑naïve non‑muscle invasive bladder cancer, showing a 55% complete response (CR) rate at 12 months in the Cohort A dataset. Presented at the AUA 2026 Annual Meeting from the open‑label ADVANCED‑2 study, the data show durable responses and a favorable safety profile — but come from a small, early‑phase cohort.
Key Takeaways
- Cohort A of ADVANCED‑2 included 31 enrolled patients, 29 evaluable for efficacy as of April 5, 2026.
- Complete response (CR) ever was 72.4% (21/29); CR at six months 66.7% (18/27); CR at 12 months 55% (11/20).
- Kaplan‑Meier six‑month CR maintenance estimated at 73.1% (95% CI 52.9–93.4); 9–12 month CR maintenance reported at 91.7%.
- Safety was favorable: most treatment‑related adverse events Grade 1 and transient, no Grade ≥3 AEs and no discontinuations; common AEs were dysuria, fatigue and hematuria.
- Company plans to finish enrollment in the registrational BCG‑unresponsive cohort of ADVANCED‑2 and to start ADVANCED‑3 (TARA‑002 vs intravesical chemotherapy) in H2 2026.
People Involved
- Jesse SheffermanChief Executive Officer, Protara Therapeutics
- Mark TysonInvestigator, Mayo Clinic Phoenix
Entities Involved
- Protara Therapeutics (NASDAQ: TARA)Sponsor and developer of TARA‑002; sponsor of ADVANCED‑2
- Mayo Clinic PhoenixClinical investigator site involved in ADVANCED‑2
- American Urological Association (AUA)Venue where Cohort A data were presented at the 2026 Annual Meeting
MarketMoodz Analysis
For investors, these Phase 2 numbers deliver a mixed signal: the dataset shows meaningful initial activity (72.4% CR ever; 55% at 12 months) and a clean safety profile, which can materially de‑risk Protara’s path toward a registrational program in a narrowed NMIBC indication. If durability holds in larger cohorts, TARA‑002 could become a partnering asset or support a registration filing in the BCG‑unresponsive setting — outcomes that would extend runway for a micro‑cap biotech that lacks scale. That said, the cohort is small (20 patients evaluable at 12 months) and open‑label, so investors should treat the results as hypothesis‑generating rather than definitive.
Context matters: regulators and potential partners will want randomized or larger single‑arm registrational evidence and consistent durability beyond 12 months. Protara’s plan to complete enrollment in the BCG‑unresponsive cohort of ADVANCED‑2 and to launch ADVANCED‑3 (a head‑to‑head versus intravesical chemotherapy) in H2 2026 aligns with that playbook, but both milestones require capital and time. Historically, micro‑caps with promising Phase 2 readouts still need clear regulatory agreement or a strategic partner to fund pivotal development — and many early successes have faltered in larger trials.
What to watch next: completion of the registrational cohort enrollment, the formal start and design details of ADVANCED‑3, additional durability and safety updates, any regulatory interactions or breakthrough designation discussions, and corporate financing or partnership announcements. Note that shares traded lower on the update (reported down ~3.77% to about $5.09 at publication), reflecting the market’s focus on small sample size and execution risk even amid encouraging efficacy signals.
Source: Original Article